Literature DB >> 16944104

Differential attenuation of d-amphetamine-induced disruption of conditional discrimination performance by dopamine and serotonin antagonists.

Michael J Dunn1, Simon Killcross.   

Abstract

RATIONALE: Recent experimental findings suggest that a core cognitive deficit of schizophrenia is the degraded ability to use task-setting cues to guide goal-directed behaviour, that this deficit is evident in acute as well as chronic schizophrenia, and that such deficits can me modelled in animals using conditional discrimination tasks.
OBJECTIVE: To establish the reversal potential of D1, D2 and 5-HT receptor antagonists acutely, and D1 and D2 receptor antagonists chronically, on d-amphetamine-induced disruption of a conditional discrimination task that depends on the ability to use task-setting cues to direct goal directed performance.
METHOD: A conditional discrimination paradigm was employed in which rats learned to respond on an appropriate lever, conditional upon specific auditory stimuli.
RESULTS: d-Amphetamine (1.5 mg/kg) disruption of conditional discrimination was attenuated by acute pre-treatment with the selective D1 antagonist SCH 23390 and the atypical anti-psychotic clozapine (Cloz). Acute pre-treatment with the selective D2 antagonist eticlopride (Eti) and the anti-psychotic haloperidol (Hal) failed to reverse d-amphetamine disruption, as did pre-treatment with the selective 5HT1A antagonist WAY 100635 and the selective 5HT2A/C antagonist ritanserin. However, Eti and Hal did reverse d-amphetamine-induced task disruption when administered chronically (as did SCH 23390, alpha-flupenthixol and Cloz).
CONCLUSIONS: These results suggest that D1 receptors are involved in tasks that require the use of conditional relationships and that D2 receptor antagonism can come to exert a similar influence after chronic treatment.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16944104     DOI: 10.1007/s00213-006-0488-y

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  22 in total

1.  D1 and D2 receptor modulation in rat striatum and nucleus accumbens after subchronic and chronic haloperidol treatment.

Authors:  M Laruelle; G E Jaskiw; B K Lipska; B Kolachana; M F Casanova; J E Kleinman; D R Weinberger
Journal:  Brain Res       Date:  1992-03-13       Impact factor: 3.252

2.  Microinjections of Sch-23390 into the ventral tegmental area and substantia nigra pars reticulata attenuate the development of sensitization to the locomotor activating effects of systemic amphetamine.

Authors:  J Stewart; P Vezina
Journal:  Brain Res       Date:  1989-08-28       Impact factor: 3.252

3.  A common action of clozapine, haloperidol, and remoxipride on D1- and D2-dopaminergic receptors in the primate cerebral cortex.

Authors:  M S Lidow; P S Goldman-Rakic
Journal:  Proc Natl Acad Sci U S A       Date:  1994-05-10       Impact factor: 11.205

4.  NNC 01-0687, a selective dopamine D1 receptor antagonist, in the treatment of schizophrenia.

Authors:  J Karle; L Clemmesen; L Hansen; M Andersen; J Andersen; C Fensbo; M Sloth-Nielsen; B K Skrumsager; H Lublin; J Gerlach
Journal:  Psychopharmacology (Berl)       Date:  1995-10       Impact factor: 4.530

5.  d-Amphetamine as a releaser or reuptake inhibitor of biogenic amines in synaptosomes.

Authors:  M Raiteri; A Bertollini; F Angelini; G Levi
Journal:  Eur J Pharmacol       Date:  1975-11       Impact factor: 4.432

6.  Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET.

Authors:  Y Okubo; T Suhara; K Suzuki; K Kobayashi; O Inoue; O Terasaki; Y Someya; T Sassa; Y Sudo; E Matsushima; M Iyo; Y Tateno; M Toru
Journal:  Nature       Date:  1997-02-13       Impact factor: 49.962

7.  Processing of context information in schizophrenia: relation to clinical symptoms and WCST performance.

Authors:  P Stratta; E Daneluzzo; M Bustini; P Prosperini; A Rossi
Journal:  Schizophr Res       Date:  2000-07-07       Impact factor: 4.939

8.  Schizophrenic deficits in the processing of context. A test of a theoretical model.

Authors:  D Servan-Schreiber; J D Cohen; S Steingard
Journal:  Arch Gen Psychiatry       Date:  1996-12

9.  Regional blockade by neuroleptic drugs of in vivo 3H-spiperone binding in the rat brain. Relation to blockade of apomorphine induced hyperactivity and stereotypies.

Authors:  C Köhler; L Haglund; S O Ogren; T Angeby
Journal:  J Neural Transm       Date:  1981       Impact factor: 3.575

10.  Continuous performance tests in schizophrenic patients: stimulus and medication effects on performance.

Authors:  E A Earle-Boyer; M R Serper; M Davidson; P D Harvey
Journal:  Psychiatry Res       Date:  1991-04       Impact factor: 3.222

View more
  12 in total

1.  A within-subject cognitive battery in the rat: differential effects of NMDA receptor antagonists.

Authors:  Sophie Dix; Gary Gilmour; Slavinka Potts; Janice W Smith; Mark Tricklebank
Journal:  Psychopharmacology (Berl)       Date:  2010-07-31       Impact factor: 4.530

2.  Switch-task performance in rats is disturbed by 12 h of sleep deprivation but not by 12 h of sleep fragmentation.

Authors:  Cathalijn H C Leenaars; Ruud N J M A Joosten; Allard Zwart; Hans Sandberg; Emma Ruimschotel; Maaike A J Hanegraaf; Maurice Dematteis; Matthijs G P Feenstra; Eus J W van Someren
Journal:  Sleep       Date:  2012-02-01       Impact factor: 5.849

3.  Prefrontal and monoaminergic contributions to stop-signal task performance in rats.

Authors:  Andrea Bari; Adam C Mar; David E Theobald; Sophie A Elands; Kelechi C N A Oganya; Dawn M Eagle; Trevor W Robbins
Journal:  J Neurosci       Date:  2011-06-22       Impact factor: 6.167

4.  Clozapine, SCH 23390 and alpha-flupenthixol but not haloperidol attenuate acute phencyclidine-induced disruption of conditional discrimination performance.

Authors:  Michael J Dunn; Simon Killcross
Journal:  Psychopharmacology (Berl)       Date:  2007-01-20       Impact factor: 4.530

Review 5.  A dialogue between the immune system and brain, spoken in the language of serotonin.

Authors:  Nicole L Baganz; Randy D Blakely
Journal:  ACS Chem Neurosci       Date:  2012-12-07       Impact factor: 4.418

6.  Pharmacological manipulations of interval timing using the peak procedure in male C3H mice.

Authors:  Fuat Balci; Elliot A Ludvig; Jacqueline M Gibson; Brian D Allen; Krystal M Frank; Bryan J Kapustinski; Thomas E Fedolak; Daniela Brunner
Journal:  Psychopharmacology (Berl)       Date:  2008-07-23       Impact factor: 4.530

7.  Dopamine modulates reward expectancy during performance of a slot machine task in rats: evidence for a 'near-miss' effect.

Authors:  Catharine A Winstanley; Paul J Cocker; Robert D Rogers
Journal:  Neuropsychopharmacology       Date:  2011-01-05       Impact factor: 7.853

8.  Proteome analysis after co-administration of clozapine or haloperidol to MK-801-treated rats.

Authors:  L Paulson; P Martin; E Ljung; K Blennow; P Davidsson
Journal:  J Neural Transm (Vienna)       Date:  2007-02-22       Impact factor: 3.850

9.  The brattleboro rat displays a natural deficit in social discrimination that is restored by clozapine and a neurotensin analog.

Authors:  D Feifel; S Mexal; Gilia Melendez; Philip Y T Liu; Joseph R Goldenberg; Paul D Shilling
Journal:  Neuropsychopharmacology       Date:  2009-03-25       Impact factor: 7.853

10.  Accelerated habit formation following amphetamine exposure is reversed by D1, but enhanced by D2, receptor antagonists.

Authors:  Andrew J D Nelson; Simon Killcross
Journal:  Front Neurosci       Date:  2013-05-15       Impact factor: 4.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.